Agenix Sells China Rights for Hepatitis B Treatment to Cinkate

Agenix, an Australian biopharma with a drug development subsidiary in Shanghai, sold its pre-clinical treatment for hepatitis B to Cinkate Pharmaceutical Intermediates for $2 million. The drug candidate, AGX-1009, is a prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor. Cinkate is a US company that is focused on drug development in China and markets Airohua® (lefluonomide) for autoimmune indications. More details.... Stock Symbol: (ASX: AGX) Share this with colleagues: // //